Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Gotlib

Showing results (111-120 of 210) with videos related to

Pageof 21
Sort By:
Blood|December 3, 2003
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesisMignon L Loh, Shashaank Vattikuti, Suzanne Schubbert, et al.
The New England Journal of Medicine|June 30, 2016
Efficacy and Safety of Midostaurin in Advanced Systemic MastocytosisJason Gotlib, Hanneke C Kluin-Nelemans, Tracy I George, et al.
Haematologica|May 11, 2023
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trialSrdan Verstovsek, Lynda Foltz, Vikas Gupta, et al.
British Journal of Haematology|June 1, 2021
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutationsNicole Naumann, Johannes Lübke, William Shomali, et al.
The Journal of Allergy and Clinical Immunology|March 31, 2012
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromesPeter Valent, Amy D Klion, Hans-Peter Horny, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2009
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generationAnnelie E Abrahamsson, Ifat Geron, Jason Gotlib, et al.
The New England Journal of Medicine|February 21, 2024
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia VeraMarina Kremyanskaya, Andrew T Kuykendall, Naveen Pemmaraju, et al.
Blood Advances|May 31, 2024
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosisAaron T Gerds, Claire Harrison, Jean-Jacques Kiladjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trialRuben A Mesa, Jason Gotlib, Vikas Gupta, et al.
Blood|January 18, 2013
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosisJason Gotlib, Animesh Pardanani, Cem Akin, et al.
Pageof 21

Showing results (111-120 of 210) with videos related to

Sort By:
Pageof 21
Blood|December 3, 2003
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesisMignon L Loh, Shashaank Vattikuti, Suzanne Schubbert, et al.
The New England Journal of Medicine|June 30, 2016
Efficacy and Safety of Midostaurin in Advanced Systemic MastocytosisJason Gotlib, Hanneke C Kluin-Nelemans, Tracy I George, et al.
Haematologica|May 11, 2023
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trialSrdan Verstovsek, Lynda Foltz, Vikas Gupta, et al.
British Journal of Haematology|June 1, 2021
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutationsNicole Naumann, Johannes Lübke, William Shomali, et al.
The Journal of Allergy and Clinical Immunology|March 31, 2012
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromesPeter Valent, Amy D Klion, Hans-Peter Horny, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2009
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generationAnnelie E Abrahamsson, Ifat Geron, Jason Gotlib, et al.
The New England Journal of Medicine|February 21, 2024
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia VeraMarina Kremyanskaya, Andrew T Kuykendall, Naveen Pemmaraju, et al.
Blood Advances|May 31, 2024
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosisAaron T Gerds, Claire Harrison, Jean-Jacques Kiladjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trialRuben A Mesa, Jason Gotlib, Vikas Gupta, et al.
Blood|January 18, 2013
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosisJason Gotlib, Animesh Pardanani, Cem Akin, et al.
Pageof 21